首页|口服中成药治疗稳定型心绞痛有效性和安全性的网状Meta分析

口服中成药治疗稳定型心绞痛有效性和安全性的网状Meta分析

扫码查看
目的:采用网状Meta分析法分析7种口服中成药(Chinese Patent Medicines,CPMs)联合常规西药(Western Medicine,WM)治疗稳定型心绞痛(Stable Angina Pectoris,SAP)的疗效和安全性.方法:检索中国知网、维普、万方、PubMed等数据库,根据纳入和排除标准筛选文献.采用Review Manager 5.3和Stata13.0进行数据分析.结果:共纳入随机对照试验研究70项,共计患者7 119例.①在心绞痛疗效方面,口服CPMs制剂联合WM均显著优于单用WM;②在心电图疗效方面,除了麝香通心滴丸(SXTX),其他口服CPMs联合WM的疗效均显著优于单用WM;③在降低心绞痛发作次数方面,除了冠心舒通胶囊(GXST)+WM方案以外,其余所有口服CPMs方案疗效均显著优于单用WM;④在缩短心绞痛持续时间方面,麝香保心丸(SXBX)、益心舒片/胶囊(YXS)和参松养心胶囊(SSYX)这3个口服CPMs品种联合WM的疗效显著优于单用WM;⑤在不良反应发生率方面,SXBX和通心络胶囊(TXL)联合WM的不良反应发生率显著高于复方丹参滴丸(FFDS)+WM方案,而FFDS+WM方案的不良反应发生率显著低于WM.对各结局指标的概率排序情况显示,方案SXBX+WM在疗效和安全性方面较优,是本研究中临床优先级最高的中西医结合方案.在安全性方面,TXL的概率排序低于WM,但是网状Meta分析结果显示,TXL+WM和单用WM之间不良反应发生率的差异不具有显著性.结论:FFDS、GXST、SXBX、SXTX、SSYX、TXL、YXS共7种口服CPMs联合WM的疗效均优于单用WM,且安全性良好,均值得临床推荐使用.口服CPMs联合WM在增强疗效的同时不会显著增加用药风险.
A network Meta-analysis of the efficacy and safety of oral Chinese patent medicine in the treatment of stable angina pectoris
Objective:To analyze the efficacy and safety of seven Chinese patent medicines(CPMs)combined with western medicine in the treatment of stable angina pectoris(SAP)by network Meta-analysis(NMA).Methods:The databases included CNKI,VIP,Wanfang,PubMed were used to retrieve literature according to the inclusion and exclusion criteria.Review Manager 5.3 and Stata 13.0 were used for data analysis.Results:A total of 70 randomized controlled trial studies involving 7 119 patients were included.① In terms of the curative effect on angina pectoris,the combination of oral CPMs preparation and western medicine(WM)was significantly better than WM alone.② In terms of electrocardiogram efficacy,except for Shexiang Tongxin Diwan(麝香通心滴丸),the efficacy of other oral CPMs plus WM regimen was significantly better than WM alone.③ In terms of reducing the frequency of angina attacks,except for the Guanxin Shutong capsules(冠心舒通胶囊)+western medicine regimen,all other oral CPM regimens showed significantly better efficacy than single western medicine regimen.④ In terms of nortening the duration of angina pectoris,the efficacy of Shexiang Baoxin Wan(麝香保心丸),the Yixinshu tablets/capsules(益心舒片/胶囊)and the Shensong Yangxin capsules(参松养心胶囊)combined with WM was significantly better than that of western medicine alone.⑤ In terms of the incidence of adverse reactions,the incidence of adverse reactions of Shexiang Baoxin Wan and the Tongxinluo capsules(通心络胶囊)combined with western medicine was significantly higher than that of the Fufang Danshen Diwan(复方丹参滴丸)+western medicine.The probability ranking of each outcome indicators showed that the scheme Shexiang Baoxin Wan+western medicine is relatively superior in terms of efficacy and safety,and is the highest clinical priority in this study.In addition,in terms of safety,the probability ranking of the Tongxinluo capsules was lower than that of western medicine,but the results of NMA showed that there was no significant difference in the incidence of adverse reactions between the Tongxinluo capsules+western medicine and western medicine alone.Conclusion:The efficacy and safety of 7 kinds of oral CPMs combined with western medicine is better than that of western medicine alone,which is worthy of clinical recommendation.Oral CPMs combined with western medicine does not significantly increase the risk of safe medication while enhancing the efficacy.

Chinese patent medicinesStable angina pectorisCoronary heart diseaseNetwork Meta-analysisSystematic review

陈曾宇、于娅

展开 >

成都市郫都区中医医院,四川 成都,611730

中成药 稳定型心绞痛 冠状动脉粥样硬化性心脏病 网状Meta分析 系统评价

2024

中医临床研究
中华中医药学会

中医临床研究

影响因子:0.839
ISSN:1674-7860
年,卷(期):2024.16(20)